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Abstract
The term paraproteinemic neuropathy describes a heterogeneous set of neuropathies characterized by the presence
of homogeneous immunoglobulin in the serum. An abnormal clonal proliferation of B-lymphocytes or plasma cells,
which may or may not occur in the context of a hematologic malignancy, produces the immunoglobulins in excess.
If malignancy is identified, treatment should be targeted to the neoplasm. Most cases, however, occur as monoclonal
gammopathy of undetermined significance. Few prospective, randomized, placebo-controlled trials are available to
inform the management of paraproteinemic neuropathies. Clinical experience combined with data from smaller,
uncontrolled studies provide a basis for recommendations, which depend on the specific clinical setting in which
the paraprotein occurs. In this review, we provide a clinically practical approach to diagnosis and management of
such patients.
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Introduction
Peripheral neuropathy is defined as a disease or degenera-
tive state of the peripheral nerves in which motor, sensory,
or vasomotor nerve fibers are affected. The condition
appears clinically as muscle weakness and atrophy,
pain, and numbness [1]. Several monoclonal antibody-
producing conditions are associated with peripheral
neuropathy, and in these circumstances, the constella-
tion of neurological symptoms are often referred to as
paraproteinemic neuropathy (PPN) [2, 3]. As neuropathy
is relatively common with M-protein and vice-versa, PPN
may therefore be defined further as a heterogeneous
group of neuropathies, which share the common feature
of a homogeneous immunoglobulin in the serum [4].
Typically manifested neurologically as a length-dependent
axonal loss sensorimotor polyneuropathy, PPN affects
some or all sensory modalities causing allodynia, hyper-
pathia, cramps, or mild distal weakness (rarely it can
be associated with more profound motor symptoms).
Sometimes there is multiorgan involvement. Peripheral
neuropathy symptoms may precede by years other clinical
symptoms or diagnosis of the antibody-producing condi-
tion, whether it be hematologic malignancy or monoclonal
gammopathy of undetermined significance [5]. Ther-
apies depend on the particular PPN subtype and the
pathophysiology involved, and range from intravenous
immunoglobulin (IVIG), plasma exchange, and corti-
costeroids to rituximab and various chemotherapies.
Background
Paraproteinemia
Paraproteins are immunoglobulins that are produced
in excess by an abnormal clonal proliferation of B-
lymphocytes or plasma cells. These monoclonal proteins
exist as heavy chain subtypes (IgG, IgA, IgG, and less
commonly IgD or IgE) and light chain subtypes (kappa or
lambda) [1]. Clonal proliferation may occur in the context
of a hematologic malignancy or a premalignancy. Com-
monly associated disorders include multiple myeloma,
cryoglobulinemia, lymphoma, amyloidosis, Waldenstrom
macroglobulinemia, and POEMS (polyneuropathy, orga-
nomegaly, endocrinopathy, M-protein spike, and skin
manifestations) syndrome [6].
Despite the range of associated hematologic disorders,
paraproteins most commonly occur as a monoclonal
gammopathy of undetermined significance (MGUS) [7, 8].
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MGUS is a common, age-related medical condition char-
acterized by an accumulation of bone marrow plasma cells
derived from a single abnormal clone without prolif-
eration of malignant cells [8–10]. Three criteria define
MGUS: A monoclonal paraprotein band less than
30 g/L (3 g/dL); plasma cells less than 10 % on bone
marrow examination; and no evidence of bone lesions,
anemia, hypercalcemia, or renal insufficiency related to
the paraprotein [11]. MGUS-associated neuropathies are
generally not treated, except in the case of a disabling
IgM monoclonal gammopathy or when associated with
chronic inflammatory demyelinating neuropathy (CIDP),
as in certain cases of IgG or IgA monoclonal gammopa-
thy. CIDP-MGUS (non-IgM) has the same clinical and
electrodiagnostic characteristics as pure CIDP and has the
same treatment choice and algorithms (please note how-
ever that many neurologists still try standard CIDP treat-
ments first before considering immunosuppression,
even though they are not as effective as in idiopathic
CIDP) [12]. In the case of IgG monoclonal gammopathy,
studies have shown improvement on impairment mea-
sures following treatment with rituximab, cyclophospha-
mide/prednisone, or fludarabine [11–13].
Multiple myeloma is part of the spectrum of dis-
eases ranging from MGUS to plasma cell leukemia,
and similar to MGUS, is characterized by proliferation
of a plasma cell clone and subsequent overabundance
of monoclonal paraprotein (M protein) [13].
Paraproteinemic neuropathy (PPN)
Several disorders of the peripheral nervous system are
closely associated with the presence of excessive amounts
of abnormal immunoglobulins in the blood [14]. PPN may
be caused by interaction of antibodies with specific anti-
genic targets on peripheral nerves or by deposition of
immunoglobulins or amyloid. The clinical presentation,
treatment, and prognosis of PPN differs based on the
subtype and associated disorders [3]. There are three
major clinical PPN subtypes:
 Distal demyelinating symmetric neuropathy
 Chronic inflammatory demyelinating
polyneuropathy (CIDP) –like
 Axonal sensorimotor peripheral neuropathy
Approximately 10 % of patients with a chronic sensori-
motor neuropathy of unknown origin have an associated
serum monoclonal gammopathy, and two-thirds of such
cases are initially classified as MGUS [15, 16].
Clinical presentation of peripheral neuropathy associ-
ated with monoclonal proteins includes general symptoms
of foot numbness, paresthesias, imbalance, gait ataxia,
dysesthesia, and lancinating pain. In early stages, general
signs include abnormal sensation in the legs referable to
conduction in large fibers (touch, joint position, vibration).
As the illness progresses, weakness in distal muscles with
variable atrophy occurs [15, 17].
Paraproteins are detected in the serum of approxi-
mately 1 % of the general population [1, 7]. The preva-
lence of paraproteinemia rises with age, up to 5.3 %
among individuals over 70 years and up to 10 % in
people older than 80 years [10]. Among patients with
cryptogenic neuropathy, the prevalence of paraproteine-
mia is 10 %. PPN is most commonly observed with IgM
gammopathy (48 %), followed by IgG (37 %), and IgA
(15 %). African Americans have a higher prevalence of
monoclonal gammopathy [5].
Paraproteinemic disorders
Each of the individual paraproteinemic disorders exhibits
a distinct neuropathic phenotype, and the typical clinical
features are described below. The prognosis is often not
well-defined and unknown in many cases.
Anti-MAG neuropathy is described as “distal acquired
demyelinating symmetric” (DADS) sensory and motor
neuropathy. It is usually very slowly progressive and pre-
dominately distal with sensory ataxia, little or no weak-
ness, and frequent tremor. This condition usually has a
benign course with little functional deterioration over
time; however, the neuropathy may evolve more rapidly
at certain stages. At least one report showed that 10 and
15 years after onset, 24 % and 50 % of patients were
disabled, respectively [18].
IgG/A MGUS with associated neuropathy resembling
chronic inflammatory demyelinating polyneuropathy (CIDP)
is a relapsing or progressive sensori-motor disorder in-
volving the peripheral nerves with symmetrical proximal
and distal weakness of the four limbs, sensory involvement
and areflexia. About 80 % of patients respond to one of
the typical CIDP treatments (please see the treatment
section). Some patients stabilize without therapy [19].
IgG/A MGUS with associated axonal neuropathy is a
sensory or sensori-motor axonal neuropathy involving
distal extremities in a length-dependent fashion. Initial
presentation typically entails distal lower limb sensory
symptoms and signs, with motor weakness at later stages.
The progression is slow and often does not require any
treatment [17].
Cryoglobulinemia (most frequently mixed cryoglobuli-
nemia) with neuropathy is characterized by multifocal
axonal neuropathy, as a mononeuropathy multiplex pat-
tern, secondary to necrotizing vasculitis. Pain can be a dis-
tinguishing feature of cryoglobulenic neuropathy. Sensory
fibers are more commonly affected than motor fibers, with
approximately 5 % of patients experiencing pure motor
neuropathy [20–22].
Primary (AL) amyloidosis coexists with multiple mye-
loma in 10 % of cases, and 20 % of patients with AL
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present with a neuropathy [14]. The neuropathy itself
is mostly symptomatic in the distal lower limbs, pre-
dominately sensory, and of the small fiber painful
type. Autonomic dysfunction is frequent. Symptoms
of amyloidosis include pain, weight loss, macroglossia,
organomegaly, or cardiomyopathy. If left untreated, it
has a poor prognosis with median survival less than
18 months from onset [23–25].
CANOMAD syndrome (Chronic Ataxic Neuropathy
with Ophthalmoplegia, M-protein, cold Agglutinins and
Disialosyl antibodies [anti-ganglioside, anti-GD1b, and
anti-GQ1b]) is a rare phenotype associated with an IgM
MGUS [26]. It may correspond to a chronic form of Miller
Fisher syndrome, a rare variant of Guillain–Barré syn-
drome that manifests with ataxia, areflexia, and ophthal-
moplegia. Ataxia is profound, severely impairing function,
but motor strength remains relatively spared [27].
POEMS (Polyneuropathy, Organomegaly, Endocrino-
pathy, M-protein, Skin changes) syndrome is a rare
entity featuring sclerotic bone lesions, Castleman’s disease
(a very rare disorder characterized by non-cancerous
growths that may develop in the lymph node tissue at a
single site or throughout the body), papilledema, ascites,
and skin changes including nail clubbing and hyperpig-
mentation [28, 29]. Neuropathy is the main feature and
often precedes the diagnosis of osteosclerotic myeloma.
Positive sensory symptoms and slowly progressive, pre-
dominately distal weakness occurs [30]. If untreated,
POEMS syndrome has a poor prognosis with a median
survival of 12–33 months [31].
Neuropathies associated with lymphoma are heteroge-
neous with variable prognosis depending on the type.
Demyelinating forms may have a more favorable prog-
nosis [32]. Aggressive B cell lymphoma, usually associated
with proximal infiltration suggested by isolated radiculo-
pathy, has a poor prognosis. Axonal multiple mono-
neuropathies related to distal infiltration have better
outcomes [33–35].
Waldenstrom macroglobulinemia (WM) can result in
peripheral neuropathy in up to 47 % of patients. Most
patients with WM-related neuropathy complain of sen-
sory loss and unsteady gait. Less commonly there is a
predominant motor neuropathy which may be associated
with elevated titers of IgM antibodies targeting ganglio-
side GM1 [36].
Testing strategy
A general and detailed neurological exam should be
performed to characterize the neuropathic phenotype.
Tests should include a hematology panel as well as serum
and urine protein electrophoresis with immunofixation.
Table 1 describes diagnostic tests, including urinalysis,
imaging studies, electrodiagnostic tests, and biopsies.
For patients who are found to have a paraproteinemia,
diagnostic testing leans towards investigations of possible
hematologic neoplasms. If none are discovered, then other
diseases should be considered, including primary (AL)
amyloidosis and cryoglobulinemia [22, 24]. Monoclonal
proteins should be characterized by protein electrophor-
esis and immunofixation of the serum and the urine. De-
tailed electrophysiology includes determination of DML
(distal motor latency)/MNCV (motor nerve conduction
velocity)/TLI (terminal latency index), assessment for CB
(conduction block)/ATD (abnormal temporal dispersion).
If results of the CBC and/or peripheral smear examination
are abnormal, a bone marrow biopsy is recommended, in
consult with a hematologist. Even if the results of the CBC
and/or peripheral smear examination are normal, then a
bone marrow biopsy is still considered and usually recom-
mended based on consultation with a hematologist before
the diagnosis of MGUS is made. A skeletal X-ray survey
can detect the presence of lytic lesions.
Cerebrospinal fluid (CSF) analysis including cytology
and neuroimaging studies (MR neurography) may exclude
leptomeningeal infiltration, especially in the presence of
lymphoma. Nerve and muscle biopsy are occasionally
performed to exclude infiltrative neoplasms, paraproteine-
mic vasculitis, or AL. If vasculitis is suspected, biopsy of
the sural nerve is indicated. Alternatively, biopsy of the
superficial peroneal nerve and peroneus brevis muscle
obtains both nerve and muscle with a single incision and
may increase the yield of identifying vasculitic pathology
by up to 10 %. In the work-up of possible AL, abdominal
fat aspiration biopsy is preferred over nerve biopsy due to
the more favorable safety profile of the former procedure,
despite lower sensitivity. If small fiber neuropathy is
suspected, epidermal nerve twig analysis via skin biopsy
may be performed.
VEGF testing for POEMS
In patients with M-protein, endocrine and skin changes,
and demyelinating polyneuropathy, testing for elevated
vascular endothelial growth factor (VEGF) may help diag-
nose POEMS. A retrospective study found that VEGF
levels in patients with POEMS syndrome were markedly
elevated compared with patients with other plasma cell
dyscrasias (P < .001), peripheral neuropathy (P < .001), and
connective tissue disease/vasculitis (P < .009). The best
VEGF cut-off for POEMS diagnosis was 146 pg/mL;
however, a cut-off of 200 pg/mL had a specificity of 95 %
with a sensitivity of 68 % in support of a POEMS diagnosis
(level of evidence: 3) [37].
Paraproteinemia treatment strategy
Many of the treatments for PPN are chemotherapy agents
that may have significant impact on lifestyle. Psychological
support for both the patient and family is often needed.
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Table 1 Diagnostic tests for PPN
Test Description Comments
Erythrocyte sedimentation rate (ESR) Venous blood sample. ESR elevation is primarily due to increased levels of Ig (clonal or polyclonal) or fibrinogen
Serum total protein and albumin Venous blood sample. Protein elevated in:
Normal range: Monoclonal gammopathy
Serum total protein: 6 to 8 g/dL Dehydration




Serum protein electrophoresis Venous blood sample. Indicated if serum protein and/or globulin is elevated or clinical findings raise suspicion
of monoclonal gammopathy.
M protein, if present, is a discrete spike in the γ, β or α2 region.
MGUS, M peak: 0.5 to 3 g/dL, amount directly related to probability of progression to
multiple myeloma or a related plasma cell malignancy.
Serum M spike present in 80 % of patients with myeloma.
Immunofixation Venous blood sample. Indicated when an M spike is found on serum electrophoresis or when clinical findings
present suspicion of multiple myeloma, other plasma cell malignancy, amyloidosis, or WM.
Monoclonal immunoglobulin:
MGUS: IgG (73 %), IgA (11 %), IgM (14 %), IgD, κ or λ light chains Defines the heavy and light chain type of the abnormal serum protein, which can
discriminate between MGUS, multiple myeloma, other plasma cell malignancies, WM,
and amyloidosis.Multiple myeloma: IgG (50 %), IgA (20 %), IgD (few), free light
chains (17 %)
WM: IgM-κ
Amyloidosis: IgG, IgA, IgD, IgM, κ or λ light chains; 30 %
non-secretory
Osteosclerotic myeloma: IgG-λ or IgA-λ
Heavy-chain disease: IgG, IgA, IgM, no light chain
Serum light chain quantitation Venous blood sample. Provides a rapid, accurate, quantitative measurement of λ and κ light-chain in serum.
κ free light chain: 3.3 to 19.4 mg/L Increased light chain levels are seen in most plasma cell disorders, especially the more
malignant disorders such as multiple myeloma.
λ free light chain: 5.7 to 26.3 mg/L Free light chain (FLC) ratio may be a risk factor for progression to malignancy [66].
Unlike urine Bence-Jones protein assays, results are not affected by changes in renal
function.













Table 1 Diagnostic tests for PPN (Continued)
Autoantibody panels Normal: Measures presence and titer of antibodies.
Absence of antibody Anti-MAG antibody assesses distal demyelinating sensory neuropathy.
Anti-GM1 antibody assesses multifocal motor neuropathy.
Anti-GQ1b antibody assesses Miller-Fisher.
Please note that absolute absence of autoantibodies is not required for a “normal” test
for many antibodies at different labs.
Cryoglobulins Normal: Serum blood specimen collected and separated while warm for cryoprecipitation over a
period of up to 7 days.
Less than 80 μg/ml At very high cryoglobulin titer states, cryoprecipitates during blood collection produce
structures on peripheral blood smears that may be mistaken for leukocytes or platelets
by automated cell differential analyzers.
24-h urine protein quantification
and electrophoreses
Detects excretion of monoclonal immunoglobulin. Dipstick test for proteinuria primarily detects albumin and often misses M protein.
Normal:
Urinary protein excretion less than 150 mg/day. Recommended for patients with serum M spike or clinically-based suspicion of
monoclonal gammopathy.
Small amount of Bence-Jones protein not uncommon
Urine immunofixation Characterizes urinary monoclonal immunoglobulin following test
of 24-h urine and should be done if serum M spike is greater than
1.5 g/dL.
Indicated if multiple myeloma, WM, primary amyloidosis, or a related disorder is
suspected, even if routine urinalysis is negative for protein, 24-h urine is within normal
limits, or if no M spike is seen on electrophoresis of concentrated urine sample.
Electrodiagnostic (electro-myelogram
and nerve conduction studies)
Determines whether symptoms are due to a muscle or nerve
disorder by measuring conduction velocities and the presence or
absence of conduction blocks.
Determines whether the polyneuropathy is axonal or demyelinating.
Tests help to localize the anatomic site of a lesion that is causing pain, and determine
the presence of active denervation.
Bone marrow aspiration and biopsy A sample is taken usually from the posterior superior iliac crest
region.
Required if a high M protein level is found to investigate the possibility of multiple
myeloma or lymphoma.
Normal result is age-appropriate cellularity and lineage
distribution and < 10 % plasma cells.
May reveal clinically inapparent involvement.
Requires local anesthesia and the assistance of an attendant.
Risk of infection and bleeding.
Radiographic skeletal bone survey Two dimensional radiographs of the entire skeleton. Survey detects lytic and sclerotic lesions as well as fractures which may be pathologic.
There is a relatively high radiation exposure.
Cerebrospinal fluid analysis Investigate CIDP and leptomeningeal lymphomatous infiltration. Elevated protein level is common in PPN.
Infiltration of the CNS by Non-Hodgkin’s lymphoma will show clonal lymphocytes.
Viral infection may result in increased CSF lymphocytes but will not be clonal.
Autoantibodies can be tested within the CSF but the results may differ depending on
the laboratory used. Absolute absence of autoantibodies is not required for a “normal”













Table 1 Diagnostic tests for PPN (Continued)
Nerve biopsy Biopsy of the superficial peroneal nerve is ideal so that a muscle
biopsy of the peroneus brevis muscle may be done simultaneously;
other choices include sural or superficial radial sensory nerves.
Identifies abnormal density of small and large axons and abnormal myelin sheaths.
Reserved for cases in which it is difficult to identify whether the process is predominantly
axon degeneration or demyelination, or for cases where there is patchy, asymmetric, or
focal involvement.
Evaluates suspected cases of infiltrative neoplasms, paraproteinemic
vasculitis, or amyloidosis.
A negative nerve biopsy does not exclude amyloid neuropathy.
Please note that as with serum and CSF autoantibody testing, results may differ
depending on the laboratory used.
Muscle biopsy See “Nerve biopsy” for best incision site. The procedure helps distinguish between an atypical neurogenic disorder and a primary
myopathic disorder.
Fat biopsy A normal result is no amyloid protein. The test is most often done when there is suspicion of amyloidosis.
Skin biopsy Examines the degree of myelination of small fiber neurons. Helps ascertain the presence or absence of small fiber neuropathy.




The scan can detect lymphadenopathy, hepatosplenomegaly, and
ascites.
Intravenous contrast is usually required for better visualization of lymphoid structures.
Positron emission tomography scan Functional images assess metabolic activity within various structures,
including lymph nodes and may detect nodal, extranodal, and
bone marrow involvement by lymphoma.
PET scan can be used concurrently with non-contrast CT scan to combine functional
and anatomic imaging.
Acute inflammation and infection can also result in increased uptake safety profile of the













As lifestyle modifications generally recommended in clin-
ical practice, patients are counseled to remain as active
as possible, abstain from alcohol, and stop smoking, if
applicable. Several specialties may collaborate on treat-
ment plans, including hematology for chemotherapy,
neurology for pain management, radiation oncology for
radiotherapy of plasmacytomas in POEMS syndrome,
surgery for removal of solitary plasmacytomas in POEMS
syndrome, and physical/occupational/recreational/speech/
rehabilitation therapy [17]. Table 2 lists treatments directed
to paraproteinemia.
The mode and method of monitoring depends on the
particular condition. Treatment decisions from a neur-
ology standpoint usually are not based only on M-protein
levels but rather the clinical picture, including severity,
progression, and topography of motor deficit all which are
important in selecting appropriate treatment. Additionally
for MGUS patients, periodic (every 6–12 months) im-
munoglobulin quantitation and serum immunofixation
may be done to determine changes in monoclonal protein
level [8]. We consider treatment (always in consult with a
hematologist) when the serum monoclonal protein rises
above a concentration of 1.5 g/dL [38, 39]. Occasionally,
serial electrodiagnostic studies are used to monitor disease
response or progression [36]. Complications from the
neuropathy itself include neuropathic ulcers and pain,
Charcot joints, orthostasis, and predisposition to periph-
eral injury given lack of sensation [40].
PPN treatment first aims for paraprotein quantity
reduction and the diminishing of cells producing the
paraproteins, which may lead to improvement of neuro-
logical symptoms. IgM PPN sometimes responds to im-
munotherapies, but the potential benefits should be
balanced against possible side effects, as well as the typic-
ally slow disease progression [18]. IgG and IgA PDN may
be indistinguishable from chronic inflammatory demyelin-
ating polyradiculoneuropathy clinically, electrophysio-
logically, and in response to treatment. The presence
of paraprotein-related vasculitis or AL may also require
treatment modification [19].
Intravenous immune globulin (IVIG)
A systematic Cochrane review identified seven randomized
controlled trials that examined the efficacy of any form of
immunotherapy in reducing disability and impairment
resulting from IgM anti-MAG paraprotein-associated de-
myelinating peripheral neuropathy. The primary outcome
measure was the change in Neuropathy Impairment scale
or Modified Rankin after six months, and secondary out-
comes included shorter-term changes in impairment scale
scores as well as paraprotein levels after six months.
None of the seven trials provided adequate evidence
to support immunotherapies based on the primary
outcome measured at six months [41]. However, two
short-term trials of IVIG showed statistically signifi-
cant improvements in Modified Rankin Scale at two
weeks and 10-m walk time at four weeks (level of
evidence, 2). Other studies have indicated that IVIG
was effective in 15 % to 20 % of patients [42–44]. A
prospective study of 22 patients indicated that IVIG
induced a short-term benefit in 50 % of patients with
IgM paraprotein-associated neuropathies (11 of 19 patients
had elevated anti-MAG antibodies) [45]. These findings
suggest IVIG may provide benefit for some patients.
IVIG adverse effects may include allergic reactions,
cephalgia, aseptic meningitis, hemolysis, renal adverse
effects mostly in sucrose-based preparations, and hyper-
coagulable states (e.g., DVT, PE, and MI).
Plasmapheresis (plasma exchange)
This blood purification procedure removes antibodies,
thereby preventing them from binding their targets. The
procedure removes the blood, separates blood cells from
plasma, and returns purified blood, diluted with a plasma
substitute, to the circulation [46]. Plasmapheresis is used
for certain patients with IgG/A MGUS-associated neur-
opathy and may be helpful in severe cases of cryoglobuli-
nemia. Plasmapheresis has only short term efficacy and
must be repeated to maintain effectiveness. The procedure
has limited utility for treatment of IgM-associated PPN.
A systematic review of treatments for IgG or IgA para-
proteinemic peripheral neuropathy identified one rele-
vant randomized controlled trial with 18 participants.
Results showed plasma exchange had modest improve-
ment over sham plasma exchange over a short-term
follow up (level of evidence: 2) [47].
Corticosteroids
A review of case reports and uncontrolled studies indi-
cated that corticosteroids, when given in conjunction with
other therapies, produced a response in about half of the
patients with high anti-MAG IgM, but was seldom effect-
ive as a single therapy [43]. Corticosteroids have potential
adverse effects on numerous organ systems (dermatologic,
metabolic, cardiovascular, immune, gastrointestinal, cen-
tral nervous system, bone), and patients receiving long-
term or high doses of corticosteroids should be monitored
for the development or worsening of these conditions.
Long-term use (usually >3 weeks) or doses greater than
physiological amounts (7.5 mg prednisone), may lead to
clinically relevant suppression of the pituitary-adrenal
axis, or exogenous Cushing syndrome. Corticosteroids
may cause immunosuppression, which may mask signs of
infection and increase patient susceptibility to infection.
Patients should not receive live attenuated vaccines during
therapy [48, 49].
Rison and Beydoun BMC Neurology  (2016) 16:13 Page 7 of 14
Table 2 Treatment for paraproteinemia
Treatment Indication Dose Major contraindications
Intravenous immune
globulin (IVIG)
FDA-approved treatment for CIDP 2 g/kg intravenously for 3–5 days, followed by maintenance
dose of 1 g/kg every 3 weeks, followed by clinical reassessment
Hypersensitivity to IVIG
FDA-approved treatment for multifocal motor
neuropathy
0.5-2.4 g/kg per month with clinical assessment followed by
clinical reassessment
IgA deficiency
Treatment for IgA/IgG-MGUS-CIDP Immunoglobulin A deficiency
Alternative treatment for IgM-MGUS-distal demyelinating
neuropathy (or rituximab, off-label use)
Treatment of CANOMAD (off label use)
Corticosteroids First line treatment for CIDP associated with M protein
(off-label use)
Prednisone: Corticosteroid hypersensitivity
An alternative treatment for IgM/A/G-MGUS (after
rituximab or plasma exchange, off label use)
1 to 1.5 mg/kg/day orally Fungal infection
Several treatment dosing regimens are available and duration is
not agreed upon.
Azathioprine Alternative immunosuppressive treatment (after IVIG or




Rituximab Alternative treatment for IgM-MGUS (off-label use) Four weekly infusions of 375 mg/m2 rituximab [51] Hypersensitivity to rituximab
Alternative therapy for multifocal motor neuropathy
(after IVIG, off label use)
Chlorambucil Alternative therapy for IgM-MGUS (off label use) 0.1 to 0.2 mg/kg orally daily for 3 to 6 weeks Hypersensitivity to chlorambucil
FDA pregnancy category D
Fludarabine Alternative therapy for IgM-MGUS (off label use) 40 mg/m2 for 5 days every 28 days Hypersensitivity to fludarabine
FDA pregnancy risk category D
Melphalan Treatment for POEMS For POEMS (high dose): 10 mg/m2 for 4 days every 28 days [58] Hypersensitivity to melphalan
In combination with prednisone as treatment for AL For AL: 0.15 mg/kg once daily for 7 days every 6 weeks, increasing
the dose by 2 mg in each 6 week course. Should be used in
combination with prednisone.
Should not be used in patients whose disease
has demonstrated prior melphalan resistance
Plasmapheresis
(plasma exchange)
Alternative treatment of IgG/A MGUS 3 to 5 exchanges every other day Risks associated with frequent vascular access
May be helpful in severe cases of cryoglobulinemia. Risk of transmission of infective agents if fresh
plasma is used as replacement fluid
Anaphylaxis and allergic reactions may occur













Table 2 Treatment for paraproteinemia (Continued)
Autologous peripheral
stem cell transplant
First line treatment of POEMS syndrome Myeloablative doses of chemotherapy and/or radiation therapy
followed by infusion of peripheral blood stem cells
Patients who undergo HCT are at risk for
bacterial, viral, and fungal infections
Alternative treatment of AL, used in combination with
melphalan
Early adverse effects include: nausea, vomiting,
diarrhea, mouth sores
Later adverse effects include: cataracts, sterility,
increased risk of other neoplasias
Radiation therapy First line treatment of dominant sclerotic plasmacytoma
in POEMS syndrome
Radiation therapy delivered to osteosclerotic lesions in doses of
40–50 Gy
Adverse effects depend upon the location of
the area irradiated
Increased risk of developing second malignancies














After IVIG or corticosteroids, azathioprine is an alterna-
tive immunosuppressive treatment for CIDP [21]. The
US FDA requires a boxed warning to advise of increased
risk of neoplasia, particularly lymphoma (hepatosplenic
T-cell lymphoma) and skin cancers associated with use
of azathioprine. The drug is a purine analog that causes
immune suppression and subnormal response to infec-
tions or vaccines. Infections should be treated vigorously
and live vaccines avoided. There is risk of irreversible or
delayed bone marrow suppression. Individuals with thio-
purine methyltransferase (TPMT) deficiency may be
unusually susceptible to myelosuppression. There is also
a risk of pancreatitis and hepatotoxicity, which may be
dose-related. A gastrointestinal hypersensitivity reaction
characterized by severe nausea and vomiting has also
been reported and may occur in the first few weeks of
treatment. Hepatic or renal impairment may require a
dose reduction. CBC, renal and liver function should be
monitored periodically.
Rituximab
This monoclonal antibody targets the CD20 antigen on
B lymphocytes and is a first-line treatment for IgM-
MGUS (off-label use). A small randomized study deter-
mined the effectiveness of rituximab versus placebo on
symptoms of neuropathy in patients with anti-MAG IgM
demyelinating polyneuropathy. Twenty-six patients were
randomized to four weekly infusions of 375 mg/m2 rituxi-
mab or placebo. After 8 months, 4 of 12 rituximab-treated
patients improved by at least one INCAT score (a measure
of leg disability) compared with 0 of 13 patients taking
placebo (P = .036) (level of evidence, 2) [50]. Another
double blind placebo controlled trial of rituximab ran-
domized 54 patients with IgM anti-MAG demyelinating
neuropathy to receive rituximab or placebo. The primary
outcome was the mean change in INCAT sensory
score at 12 months, which showed no significant dif-
ference between treatment arms. However, with six
patients in the rituximab group dropping out of the
study, the per protocol analysis showed significant im-
provement in the rituximab group for secondary end-
points of INCAT disability scale and self-evaluation
scale (P = .027 and P = .016, respectively) [51]. Both trials
indicate statistically significant improvement in clinical
rating scales (as secondary outcomes in some cases)
suggesting that the use of rituximab for patients with
anti-MAG IgM demyelinating polyneuropathy may
provide benefit. Although some may not improve and
the worsening is part of the disease progression, some
patients may worsen after rituximab, especially if IgM
levels are very high, similarly as with Waldenstrom’s
macroglobulinemia [52–54].
Chlorambucil
The alkylating agent chlorambucil is well tolerated by
most patients but immunosuppression and bone marrow
suppression may develop, which may lead to an increased
susceptibility to infections or bleeding. Neutropenia can
occur after the third week of chlorambucil therapy and
continue for up to 10 days after the last dose. CBC should
be monitored weekly.
Fludarabine
Fludarabine is used as alternative therapy for IgM-MGUS,
and the efficacy of the cytotoxic purine antimetabolite has
been demonstrated in very small case series, both alone
and in combination with rituximab [55, 56]. Use of fludar-
abine can cause severe bone marrow suppression. Life-
threatening and sometimes fatal autoimmune hemolytic
anemia and immune thrombocytopenic purpura have
been reported following one or more cycles of fludarabine
therapy in approximately 5 % of patients. Nausea/vomiting
during intravenous fludarabine treatment is common.
CBC should be monitored weekly.
Melphalan
Melphalan in combination with prednisone may reduce
the monoclonal protein level and even prolong survival
in AL, but the specific effect of this regimen on peripheral
neuropathy is not known [57]. Melphalan is used for treat-
ment of POEMS syndrome. A study from China on 31
patients with POEMS reported that high-dose melphalan
plus dexamethasone resulted in good hematologic and
neurologic responses [58]. The drug may cause a second-
ary malignancy; melphalan is leukemogenic in humans.
Myelosuppressive effects of melphalan can increase the
risk of infection or bleeding. The dosage of melphalan
should be reduced or therapy discontinued at the first
signs of neutropenia or thrombocytopenia. CBC should be
monitored closely.
Symptomatic treatment strategy
Symptomatic treatment of the neuropathy itself usually in-
volves membrane stabilizers, tricyclic anti-depressants, and/
or serotonin-norepinephrine reuptake inhibitors. Guide-
lines from the American Academy of Neurology summarize
evidence-based information on pharmacologic and non-
pharmacologic treatments for painful neuropathy [59].
Gabapentin
A structural analogue of the inhibitory neurotransmitter
γ-aminobutyric acid (GABA), gabapentin is a first line
treatment for neuropathic pain and is effective for a
variety of neuropathic pain conditions. It exerts its anti-
nociceptive effect by binding the alpha-2 delta calcium
channel in the dorsal horn of the spinal cord. It should
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be used with caution in renal insufficiency; the dose
must be adjusted.
Pregabalin
Designed as a more potent successor to gabapentin,
pregabalin is effective for a variety of neuropathic condi-
tions. It should be used with caution in renal insufficiency;
the dose must be adjusted.
Valproate
Valproate agent should be used with caution in hepatic
impairment; dose reduction is required. The US FDA
requires a boxed warning to advise of hepatic failure
resulting in fatalities and to advise of teratogenic effects,
such as neural tube defects, when used in pregnancy.
Dextromethorphan
N-methyl-d-aspartate (NMDA) antagonists such as dex-
tromethorphan block the activation of NMDA recep-
tors, which is contributory to development of central
sensitization resulting in hyperalgesia, hyperpathia, allody-
nia, and reduced functionality of opioid receptors. Side
effects may include light-headedness, drowsiness, visual
disturbances, and hot flushes; the agent should be
used with caution in patients who are sedated or de-
bilitated [60].
Tramadol
The mixed opioid, mu agonist and inhibitor of uptake of
serotonin and norepinephrine, should be used with cau-
tion in renal and hepatic impairment; dose reduction is
required. In rare instances anaphylactic reactions have
been reported. The agent may cause CNS depression,
which may impair physical or mental abilities.
Duloxetine
Duloxetine is a serotonin-norepinephrine reuptake inhibi-
tor (SNRI) used for symptomatic treatment for peripheral
neuropathy. It is FDA approved for the treatment of dia-
betic peripheral neuropathic pain (DPNP). The US FDA
requires a boxed warning to advise of suicidal thinking
and behavior in children, adolescents, and young adults
(18 to 24 years of age) with major depressive disorder
(MDD) and other psychiatric disorders.
Amitriptyline
Amitriptyline is the most widely used tricyclic anti-
depressant (TCA), and is used off-label for symptomatic
treatment of peripheral neuropathy. The US FDA requires
a boxed warning to advise of suicidal thinking and behav-
ior in children, adolescents, and young adults (18 to
24 years of age) with major depressive disorder and other
psychiatric disorders.
Venlafaxine
The serotonin/norepinephrine reuptake inhibitor (SNRI)
venlafaxine is used off-label for symptomatic treatment
of peripheral neuropathy. The US FDA requires a boxed
warning to advise of suicidal thinking and behavior in
children, adolescents, and young adults (18 to 24 years
of age) with major depressive disorder and other psychi-
atric disorders. In patients with renal impairment (GFR
10–70 ml/min), reduce total daily dose by 25 to 50 %. In
patients with mild to moderate hepatic impairment,
reduce total daily dose by 50 %.
Autologous peripheral stem cell transplantation
As a first line treatment for POEMS syndrome and alter-
native treatment (in combination with melphalan) for AL,
autologous peripheral stem cell transplantation entails
administration of myeloablative doses of chemotherapy
and/or radiation therapy followed by infusion of periph-
eral blood stem cells [61, 62].
Granulocyte colony stimulating factor (G-CSF) is given
to stimulate peripheral blood stem cells followed by
hematopoietic stem cell mobilization four to six days
later. Peripheral blood progenitor cells (PBPCs) are mobi-
lized using a variety of techniques. Following initiation of
a mobilization regimen, patients are monitored by periph-
eral blood CD34 counts. Apheresis begins when the
peripheral CD34+ counts have reached a target level (i.e.,
10 CD34 cells/μl). After completion of the preparative
chemotherapy, PBPCs are reinfused. A period of pancyto-
penia follows and red blood cell and platelet transfusions
are administered as necessary while G-CSF is used to
speed neutrophil engraftment. Lifelong follow up is neces-
sary to monitor for complications and recurrence. Patients
are at risk for bacterial, viral, and fungal infections. Early
adverse effects include nausea, vomiting, diarrhea, and
mouth sores; later adverse effects include cataracts, steril-
ity, and increased risk of other neoplasias.
Efficacy of the procedure for peripheral neuropathy
symptom improvement is based on small case series,
and data suggest that most patients achieve at least some
neurologic improvement. A small study of 9 patients with
POEMS syndrome evaluated the extent and time course
of neurologic improvement after autologous peripheral
blood stem cell transplantation. Within 3 months, neuro-
logic improvement began, and all the patients showed
substantial neurologic recovery during the next 3 months.
At the end of follow-up periods (8 to 49 months, me-
dian 20 months), neuropathy was still improving and
no patients had recurrence of symptoms (level of evi-
dence: 3) [62].
Radiation therapy
Radiation therapy as a first line treatment for dominant
sclerotic plasmacytoma in POEMS syndrome is delivered
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to osteosclerotic lesions in doses of 40–50 Gy. More than
50 % of patients treated with radiation show improvement
of the neuropathy, but improvement in some patients may
be delayed, occurring after six months or longer [31].
Physical, occupational, speech, recreational, and
rehabilitative therapies
For training in performance of activities of daily living,
physical therapy that focuses on compensatory strategies
to accommodate for limbs with a loss of sensation and
weakness is often done by patients with peripheral neu-
ropathies. Amyloidosis as a paraprotein can cause gas-
troparesis/dysphagia, which is also seen in CANOMAD
and can result from medication toxicity. Speech therapy
focused on training in swallowing may attenuate symp-
toms in patients suffering gastroparesis or dysphagia
[63, 64]. Recreational therapy helps patients recover
basic motor functioning, to build confidence and socialize
more effectively. Treatments may incorporate arts and
crafts, sports, games, dance, drama, and/or music. Patients
with chronic disease, especially the elderly, who are iso-
lated and at risk for depression, may benefit from these
therapies, which can improve socialization and diminish
isolation.
Orthotics
For the prevention of foot ulcers and infections, orthotics
are molded cushion inserts for the foot that distribute
pressures, reduce high stress areas, and provide shock
absorption.
Acupuncture
A method of Chinese medicine aims to produce analgesia
by insertion of sharp, thin needles into the body at very
specific points. Acupuncture has produced improvement
in both subjective symptoms and objective nerve conduc-
tion study findings [65].
Transcutaneous electrical nerve stimulation (TENS)
TENS is a form of electroanalgesia that reduces pain
through nociceptive inhibition at the presynaptic level
in the dorsal horn of the spinal cord. A TENS unit
consists of 1 or more electrical-signal generators, a bat-
tery, and a set of electrodes. The TENS unit is small and
programmable, and the generators can deliver trains of
stimuli with variable current strengths, pulse rates, and
pulse widths. Patients may experience skin irritation due
to drying out of the electrode gel. TENS is contraindicated
in patients with a demand-type pacemaker.
Conclusions
Individual paraproteinemic disorders exhibit distinct neuro-
pathic phenotypes, often with characteristic, identifiable
clinical features. Frequently, prognoses are not well-defined,
and in many cases, unknown. Testing should include
a general and detailed neurological exam to characterize
phenotype, and may include various diagnostic tests de-
pending on the case. PPN treatment often calls for collab-
oration among several specialties, including hematology,
neurology, radiation oncology, surgery, and physical/occu-
pational/recreational/speech/rehabilitation therapy. Treat-
ments for PPN often involve chemotherapy agents that
may significantly impact a patient’s lifestyle. For these
individuals and their families, psychological support is
often needed.
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